The Venture Codex Logo

The Venture Codex

Atinum Investment

Je-il Building 9 Teheran-ro 103-gil Gangnam-gu Fl 2, Seoul, Seoul-t'ukpyolsi, 06173, South Korea

Overview

Atinum Partners is a venture capital firm that invests in the growth stage startups in the IT, biotech, and healthcare sectors.

Total investments
51
Lead investments
13
Investments · 12mo
11
Active investors
7

Sector focus

  • Biotechnology
  • Energy
  • Finance
  • Financial Services
  • Information Technology
  • Renewable Energy
  • Venture Capital
Visit website

Investment portfolio

  • Modhaus

    Led · Series B · Aug 2026

    Modhaus operates a multi-artist IP system and the fan-participation platform Cosmo, which enables fans to influence artist decisions such as title songs, activity units, and concert set lists. The company manages artist IPs including TripleS, Artemis, and IDENTI and reported ₩32.3 billion in revenue in 2025 with annual album sales totaling 1.16 million. Notable releases cited include TripleS’s third full album 'Love & Pop pt. 1' (560,000 initial copies) and IDENTI’s third EP 'itsnotover' (580,000 initial copies). Cosmo has recorded 530,000 cumulative subscribers, 170,000 monthly active users, and 20 million cumulative copies of its digital photocard product 'Objekt.' Artemis completed a 28-city world tour, contributing to overseas fandom expansion. Modhaus plans to grow new artist IP, proceed with IDENTI’s full 24-member activities and new artist launches, and upgrade Cosmo’s overseas services.

  • Linq

    Led · Series A · Jul 2026

    LinqAlpha builds a platform that lets institutional investors deploy specialized AI agents that synthesize thousands of signals and learn each user's unique investment framework to surface differentiated insights. The company was founded by Jacob Choi, Subeen Pang, Jin Kim, and Hojun Choi and brings together former Goldman Sachs analysts and MIT computer science PhDs. Since launch, LinqAlpha has been adopted by over 70 financial institutions across the U.S., Europe, and Asia, including sell-side teams at investment banks and buy-side clients such as Causeway Capital Management and Schonfeld Strategic Advisors. Collectively, its buy-side clients manage more than $5 trillion in assets. LinqAlpha is headquartered in New York and plans to use its Series A proceeds to expand its global team, deepen dataset integrations, and accelerate deployment across equities, macro, credit, and multi-asset strategies. The company frames its product as an "Alpha Intelligence Layer" designed to help institutional teams synthesize fast, interconnected public-market signals into actionable judgment.

  • BiteLab

    Participated · Equity · May 2026

    BiteLab develops and sells proprietary brands, including hair care brand lilyeve, skincare brand Saekdong Seoul, and lifestyle brand Baruner. Lilyeve approaches hair loss treatment from a scalp-structure perspective and has gained distinction in Amazon’s U.S. hair care category, while Baruner is expanding a lineup of ergonomics-based device products and Saekdong Seoul blends Korean aesthetics with modern dermatological science. Founded in 2020, the company grew without external capital and posted approximately 60 billion won in sales last year. BiteLab is expanding its presence in North America, Asia, and the Middle East. Following its recent fundraising, the company plans to invest in strategic product R&D, upgrade its business infrastructure, and hire more than 30 domestic and international professionals to support growth.

  • MustBio

    Participated · Series C · Mar 2026

    MustBio develops next-generation immuno-oncology therapies using a multi-antibody platform called BICSTA and a tumor-selective immunocytokine platform called STARKINE. The company is advancing a portfolio of tri-specific fusion immuno-oncology candidates, with lead programs including MB5 (an IL-2–based therapeutic in clinical development) and MB7 (an IL-21–based program in R&D). Since its founding in 2021, MustBio has raised a total of 635억원 across prior rounds and the recent Series C. The firm has entered collaboration and licensing arrangements with Celltrion and was selected for JLABS Korea and the Seoul BioHub open innovation programs. Proceeds from the Series C are earmarked to accelerate MB5 clinical work, advance MB7 R&D, expand the pipeline, and support global business development and potential technology licensing. Management has stated plans to pursue additional tri-specific antibody R&D and broaden global partnerships.

  • Rideflux

    Led · Equity · Dec 2025

    RideFlux is a South Korean startup focused on end-to-end AI-based autonomous driving software that powers both passenger and freight vehicles. The company runs the country’s only licensed driverless pilot with no safety driver, accumulating more than 2,300 hours of data in Seoul’s Sangam district. It has also operated autonomous public transportation services in Seoul, Busan, Sejong and Jeju, and recently began a Level 4 autonomous car-sharing pilot under a government project. Commercial plans for 2024 include launching paid middle-mile autonomous freight transport with partners such as Samdasoo and expanding into robotaxi services. RideFlux claims to be the only domestic operator capable of hub-to-hub autonomous truck runs that cover highways and surrounding urban roads. To support expansion, the company is advancing its driverless technology and intends to leverage government-designated autonomous driving pilot cities for large-scale commercialization. Financially, RideFlux has raised approximately 75.2 billion won to date and targets a KOSDAQ listing in the second half of next year.

Team

  • Ki Chun Shin

    VP & CEO

  • Cheuk Kim

    chief managing director

    LinkedIn
  • Sangmin David Lim

    LinkedIn
  • Park Chan-hoon

    Chief